Jump to content

This site is currently in alpha, so you will run into rough edges.

Please send feedback or ideas to connect@deeptech.wiki

Neurowyzr: Difference between revisions

From The Deep Tech Wiki
Created page with "{{Draft}} {{Infobox Startup |logo=Neurowyzer-logo.png |status=Active |website=https://neurowyzr.com/ |vertical=Medtech |trl=Deployment (TRL 7-8) |latest_funding=Series A |founding_year=2019 |headquarters=Singapore |active_in=Australia, United States, India, Malaysia, Indonesia, Thailand, Vietnam, United Kingdom }} A brief overview of {{PAGENAME}} here ==Technology== Describe the underlying science and technology of the startup here. Ideally, it should provide a layma..."
 
 
Line 1: Line 1:
{{Draft}}
{{Infobox Startup
{{Infobox Startup
|logo=Neurowyzer-logo.png
|logo=Neurowyzer-logo.png
Line 11: Line 10:
|active_in=Australia, United States, India, Malaysia, Indonesia, Thailand, Vietnam, United Kingdom
|active_in=Australia, United States, India, Malaysia, Indonesia, Thailand, Vietnam, United Kingdom
}}
}}
A brief overview of {{PAGENAME}} here
 
{{PAGENAME}} is a Singapore-based healthtech startup specializing in enhancing brain health and developing state-of-the-art technologies to mitigate early brain decline.


==Technology==
==Technology==
Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key differentiators and/or novel or proprietary scientific breakthroughs being commercialised by the startup.
The startup's first product is an online gamified digital neuroscience assessment that significantly reduces the time and dollar burden of traditional cognitive testing<ref name=":0">{{Cite web |last=Staff |first=TechNode Global |date=2023-08-24 |title=Singapore's Neurowyzr raises additional $2.1M in seed funding co-led by Jungle Ventures and Peak XV’s Surge |url=https://technode.global/2023/08/24/singapores-neurowyzr-raises-additional-2-1m-in-seed-funding-co-led-by-jungle-ventures-and-peak-xvs-surge/ |access-date=2025-12-05 |website=TNGlobal |language=en-US}}</ref>. This product has been notified with the respective regulatory bodies in Singapore, India, Malaysia, Indonesia, Thailand, Australia, Vietnam, United Kingdom and the United States.
 
==Intellectual Property==
The startup currently owns or licenses the following patents:
* ''Patent 1''
* ''Patent 2''
Participation in any technology transfer programmes may be worth describing here as well.
 
==Business Model==
Describe the startup's business model here, with emphasis on any key differentiators or business model innovations.
 
==Traction==
==Traction==
List notable customers or partnerships here. Awards should not be listed here, but under "Accolades" instead
Neurowyer's digital neuroscience assessment has been used across many of Singapore's health screening centers, general practitioners (GP) clinics, community care, and specialist centers, including Parkway Shenton, SATA Commhealth, Farrer Park Hospital, MHC Medical Centre (Amara), and O’Joy<ref name=":0" />.


==Accolades==
It has also been piloted in one of India's largest private hospital chains<ref name=":0" />.
List awards received by the startup here.


==Funding==
==Funding==
Describe the startup's funding history here. Include investors in the table below.{{Startup/Funding history}}
In 2023, Neurowyzer raised a seed round lead by Jungle Ventures and Peak XV’s Surge<ref name=":0" />.{{Startup/Funding history}}
 
== See also ==
* List any other pages directly relevant to {{PAGENAME}}


== References ==
== References ==
{{Reflist}}
{{Reflist}}

Latest revision as of 03:34, 5 December 2025


Neurowyzr is a Singapore-based healthtech startup specializing in enhancing brain health and developing state-of-the-art technologies to mitigate early brain decline.

Technology

The startup's first product is an online gamified digital neuroscience assessment that significantly reduces the time and dollar burden of traditional cognitive testing[1]. This product has been notified with the respective regulatory bodies in Singapore, India, Malaysia, Indonesia, Thailand, Australia, Vietnam, United Kingdom and the United States.

Traction

Neurowyer's digital neuroscience assessment has been used across many of Singapore's health screening centers, general practitioners (GP) clinics, community care, and specialist centers, including Parkway Shenton, SATA Commhealth, Farrer Park Hospital, MHC Medical Centre (Amara), and O’Joy[1].

It has also been piloted in one of India's largest private hospital chains[1].

Funding

In 2023, Neurowyzer raised a seed round lead by Jungle Ventures and Peak XV’s Surge[1].

Funding History
Investor Round
Surge Series A
Jungle Ventures Series A

Note: This list is community-maintained and may be incomplete or contain inaccuracies.

References

  1. 1.0 1.1 1.2 1.3 Staff, TechNode Global (2023-08-24). "Singapore's Neurowyzr raises additional $2.1M in seed funding co-led by Jungle Ventures and Peak XV's Surge". TNGlobal. Retrieved 2025-12-05.